Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C22H22NO4S2.Ca |
Molecular Weight | 897.167 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C([O-])=O)SC3=CC=CC=C3.C[C@H](CSC(=O)C4=CC=CC=C4)C(=O)N5C[C@H](C[C@H]5C([O-])=O)SC6=CC=CC=C6
InChI
InChIKey=NSYUKKYYVFVMST-LETVYOFWSA-L
InChI=1S/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) |
10.9 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOPRANOL Approved UseZOPRANOL is indicated for the treatment of mild to moderate essential hypertension. Launch Date2000 |
|||
Primary | ZOPRANOL Approved UseZOPRANOL is indicated for the treatment initiated within the first 24 hours of patients with acute myocardial infarction with or without signs and symptoms of heart failure. Launch Date2000 |
PubMed
Title | Date | PubMed |
---|---|---|
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). | 1989 |
|
Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. | 1989 Mar |
|
Zofenopril after anterior myocardial infarction. | 1995 Jun 22 |
|
Effect of Zofenopril on regeneration of sciatic nerve crush injury in a rat model. | 2009 Jun 9 |
|
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). | 2012 |
|
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability. | 2016 Jul 5 |
|
Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies. | 2017 Jan |
Sample Use Guides
The usual effective dose in hypertension is 30 mg/day (in patients without volume or salt depletion) and the starting dose is 7.5 or 15 mg/day (in patients with volume or salt depletion). In acute myocardial infarction the treatment scheme is the following: 7.5 mg every 12 h (1st and 2nd day); 15 mg every 12 h (3rd and 4th day); 30 mg every 12 h (from 5th day).
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.nevapress.com/cdr/full/17/2/115.pdf
Zofenopril (36 uM) significantly increased coronary flow after 5 min of incubation with isolated rat hearts.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
U-63
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
DBSALT002196
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
m11656
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
259493
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
88ZQ329PU2
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
100000091302
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
SUB05191MIG
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
3033690
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
82600
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
C82220
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
81938-43-4
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
DTXSID1048625
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL331378
Created by
admin on Fri Dec 15 15:22:19 GMT 2023 , Edited by admin on Fri Dec 15 15:22:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD